Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. TScan Therapeutics's
Operating Income
for the
three
months ended in Jun. 2026 was $-30.49 Mil. TScan Therapeutics's Interest Expense for the
three
months ended in Jun. 2026 was $-0.70 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for TScan Therapeutics's Interest Coverage or its related term are showing as below:
TCRX's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 106.125 * Ranked among companies with meaningful Interest Coverage only.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
TScan Therapeutics Interest Coverage Related Terms
TScan Therapeutics Interest Coverage Historical Data
* Premium members only.
The historical data trend for TScan Therapeutics's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
TCRX vs MCRB, HYPD, ELOX: Interest Coverage Comparison
For the Biotechnology subindustry, TScan Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TScan Therapeutics Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TScan Therapeutics's Interest Coverage distribution charts can be found below:
* The bar in red indicates where TScan Therapeutics's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
TScan Therapeutics did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
TScan Therapeutics (TCRX) has a Interest Coverage of 0 (At Loss) as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on TScan Therapeutics and its competitors. According to the industry distribution chart, TScan Therapeutics ranks #999999 out of 372 companies in the Biotechnology industry.
Is TScan Therapeutics' Interest Coverage too high?
TScan Therapeutics' current Interest Coverage is 0 (At Loss). Based on the distribution chart, TScan Therapeutics ranks #999999 out of 372 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TScan Therapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TScan Therapeutics' Interest Coverage compare to MCRB and HYPD?
According to the Biotechnology industry distribution chart, TScan Therapeutics ranks #999999 out of 372 companies for Interest Coverage. This places TScan Therapeutics in the lower half of its industry. The industry median Interest Coverage is 106.13. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.13, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on TScan Therapeutics and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TScan Therapeutics's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TScan Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TScan Therapeutics (TCRX) is currently considered Possible Value Trap. The stock's GF Value™ is $1.32, compared to a current price of $0.67 — trading 49.3% below its estimated fair value. The current Interest Coverage is 0 (At Loss). TScan Therapeutics' overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For TScan Therapeutics (TCRX), the current Interest Coverage is 0 (At Loss) as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TScan Therapeutics (TCRX) Overvalued in 2026?
Based on GuruFocus' analysis, TScan Therapeutics stock appears to be undervalued.
The current stock price of $0.67 is trading 49.3% below its estimated GF Value™ of $1.32.
GuruFocus considers TScan Therapeutics to be Possible Value Trap.
Key valuation signals for TCRX:
Interest Coverage: 0 (At Loss)
GF Value™: $1.32 vs. price of $0.67 (49.3% below fair value)
No single metric tells the full story. See the TCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
44GF Score
Get the complete analysis for TCRX
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TCRX has been successfully added to your 
